🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT02117089
Active, not recruiting Not applicable

Upper Limb Rehabilitation After Stroke Assisted With a Hybrid Electrical Stimulation (ES)-Robot System

NCT02117089 · tracked via the Priya Life Science China tracker
Sponsor
The Hong Kong Polytechnic University
Phase
Not applicable
Started
2013-10
Last updated
2026-09-21

Condition(s) studied

Stroke

Investigational drug(s) / intervention(s)

Electrical Stimulation; Rehabilitation Robot

Electrical Stimulation; Rehabilitation Robot: The recruited subjects will receive 20-session device assisted upper limb training with an intensity of 3 to 5 sessions/week, which will be finished within 7 consecutive weeks. In each session, the subjects will conduct the system assisted and task-oriented upper limb training for 1.5 hours.

Study summary

The purpose of this study is to investigate the combined training effectiveness of mechanical robot and neuromuscular electrical stimulation on upper limb rehabilitation after stroke.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: The recruited subjects will * have unilateral ischemic brain injury or intracerebral hemorrhage at least 6 months after the onset of single stroke * have moderate level of motor impairment in the affected upper limb, assessed by Fugl-Meyer Assessment (9\<shoulder/elbow\<27; 6\<wrist/hand\<18) * have enough cognition to be able to follow the training protocol as assessed by Mini-metal State Examination (MMSE\>21) * have detectable EMG signals (3 times of the standard deviation above the baseline) from the upper limb muscles.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Hong Kong Polytechnic University Hong Kong China

More The Hong Kong Polytechnic University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02117089 on ClinicalTrials.gov ↗ ← All trials in China